We’ve often complained that the names of specialty pharmacies selected as limited distribution partners for new therapies are not released at the time of FDA approval (why that is the case is beyond my understanding). However, we are seeing more manufacturers allowing their SP partners to announce that they are the pharmacy of record for their new LD therapy.
As requested, we are sending an update with information from some recent press releases.
We will periodically send similar updates as information becomes available.
Amber Specialty Pharmacy
Amber Specialty Pharmacy has announced that it has been selected as one of three specialty pharmacy providers for Rezurock (belumosudil) for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGVHD).
Biologics by McKesson
Biologics has announced that it has been selected as a specialty pharmacy provider for Rezurock (belumosudil) for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGVHD).
Onco360
Onco360 has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for Welireg (belzutifan), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease.
Orsini Specialty Pharmacy
Orsini has announced that it has been awarded access to three recently approved therapies:
Aduhelm indicated for the treatment of Alzheimer’s.
Nexviazyme (avalglucosidase alfa-ngpt) from Genzyme, indicated to treat patients 1 year of age and older with late-onset Pompe disease.
Tiopronin for the Treatment of Severe Homozygous Cystinuria, the first available generic version of Thiola® (tiopronin).
